A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.
A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.
2018 was a big year for industry news. Here's what might happen next in artificial intelligence, the 2020 presidential election, pharma, and more.
Some of our 2018 predictions on consolidation, pharma, and investment came true, while others were less predictable.
Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.
As merger activity heightens, some leverage retail with pharma to meet consumer demand.
Once J.P. Morgan Healthcare Week comes to a close, companies will need to show as much as they tell.
Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.
Seeing a return on investment in pharma marketing means understanding what happens to every dollar.
Those challengers who address critical patient needs beyond traditional treatment will become a force to be reckoned with.
Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.
